Medical management of Ménière's disease: a 10-year case series and review of literature.
Ménière's disease is frequent in our area. It is a disabling pathology that affects the patient's quality of life. Its etiology and pathophysiology remain unclear and there are some therapeutic alternatives with controversial results. We present our series and treatment protocol for Ménière's disease and discuss the current evidence regarding its medical treatment. In the last 10 years, 252 patients were diagnosed with Ménière's disease based on their symptoms, and the results of tonal audiometry, videonystagmography and caloric stimulation tests. All cases received medical treatment according to our management protocol. Ménière's disease is more frequent in women (54.76%); 83.73% of cases are unilateral. Among these, vertigo was observed in 93.7%, hearing loss in 88.1%, tinnitus in 86.1% and pathologic caloric stimulation tests in 71% (88.27% with a reduced vestibular response). A 5-year follow-up was performed in 89.6% of the patients. Subjective improvement as reported by patients was achieved in 94.4% of the cases. There is great controversy about the medical treatment of Ménière's disease. We found no evidence for the most adequate medical treatment among the different alternatives described in literature. The patient's acceptance and understanding of the disease is very important.
Martín González
C
C
Department of Otolaryngology, Hospital Universitario Puerta de Hierro-Majadahonda, C/Manuel de Falla, 1, 28220, Majadahonda, Madrid, Spain. micrisele@yahoo.es
González
F M
FM
Trinidad
A
A
Ibáñez
A
A
Pinilla
M
M
Martínez Ruiz-Coello
A
A
Rodríguez Valiente
A
A
López-Cortijo
C
C
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000617:Aminoglycosides / Q000627:therapeutic use; D001621:Betahistine / Q000627:therapeutic use; D002150:Caloric Tests; D003131:Combined Modality Therapy; D004584:Electronystagmography; D005260:Female; D017442:Histamine Agonists / Q000627:therapeutic use*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008297:Male; D008575:Meniere Disease / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D004856:Postural Balance / Q000187:drug effects; D012189:Retrospective Studies; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014722:Vestibule, Labyrinth / Q000187:drug effects*; D014741:Video Recording
D000305:Adrenal Cortex Hormones; D000617:Aminoglycosides; D017442:Histamine Agonists; D006993:Hypnotics and Sedatives; D014665:Vasodilator Agents; D001621:Betahistine
Curr Opin Otolaryngol Head Neck Surg. 2006 Oct;14(5):329-31
16974146
Otol Neurotol. 2008 Jan;29(1):33-8
18199956
Otol Neurotol. 2001 Mar;22(2):210-4
11300271
Otol Neurotol. 2007 Dec;28(8):1140-4
18084826
ORL J Otorhinolaryngol Relat Spec. 1986;48(5):287-92
3537899
Curr Opin Neurol. 2005 Feb;18(1):23-8
15655398
Otolaryngol Head Neck Surg. 2005 Aug;133(2):285-94
16087029
Lancet. 2008 Aug 2;372(9636):406-14
18675691
Laryngoscope. 1998 Oct;108(10):1446-9
9778281
Otol Neurotol. 2007 Aug;28(5):696-9
17468673
Laryngoscope. 2003 May;113(5):815-20
12792316
Am J Otol. 1998 Mar;19(2):196-201
9520056
Arch Otolaryngol Head Neck Surg. 2008 Nov;134(11):1149-54
19015442
Laryngoscope. 1997 Feb;107(2):211-5
9023245
Psychosom Med. 2006 Sep-Oct;68(5):762-9
17012531
Acta Otolaryngol Suppl. 1991;490:1-10
1763646
Otolaryngol Head Neck Surg. 2009 Apr;140(4):477-9
19328333
J Psychosom Res. 2009 Feb;66(2):111-8
19154853
Laryngoscope. 2008 Jun;118(6):1099-108
18418279
Curr Opin Otolaryngol Head Neck Surg. 2008 Oct;16(5):434-40
18797285
Laryngoscope. 2004 Dec;114(12):2085-91
15564826
Ear Nose Throat J. 2006 Aug;85(8):494, 496, 498
16999055
Eur Arch Otorhinolaryngol. 2006 Sep;263(9):791-7
16724210
Otol Neurotol. 2005 Jan;26(1):74-81
15699723
Arch Otolaryngol Head Neck Surg. 2006 Dec;132(12):1311-6
17178941